Brokerages Set Urogen Pharma Ltd (URGN) PT at $65.25
Urogen Pharma Ltd (NASDAQ:URGN) has been given a consensus rating of “Buy” by the ten brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $65.25.
A number of research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Urogen Pharma in a research note on Thursday, September 13th. They issued a “buy” rating and a $70.00 price target on the stock. Oppenheimer set a $75.00 price target on Urogen Pharma and gave the company a “buy” rating in a research note on Tuesday, August 14th. Finally, Cowen reissued a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, August 14th.
URGN traded up $2.99 during mid-day trading on Friday, reaching $44.76. The stock had a trading volume of 72,812 shares, compared to its average volume of 109,403. The firm has a market capitalization of $649.48 million, a price-to-earnings ratio of -20.92 and a beta of 2.08. Urogen Pharma has a 52 week low of $25.56 and a 52 week high of $69.57.
Several hedge funds have recently bought and sold shares of URGN. Menora Mivtachim Holdings LTD. lifted its stake in shares of Urogen Pharma by 35.5% in the 1st quarter. Menora Mivtachim Holdings LTD. now owns 2,045,629 shares of the company’s stock valued at $101,647,000 after purchasing an additional 535,622 shares during the period. Citadel Advisors LLC lifted its stake in shares of Urogen Pharma by 294.6% in the 2nd quarter. Citadel Advisors LLC now owns 321,034 shares of the company’s stock valued at $15,974,000 after purchasing an additional 239,676 shares during the period. Millennium Management LLC lifted its stake in shares of Urogen Pharma by 1,285.4% in the 1st quarter. Millennium Management LLC now owns 159,113 shares of the company’s stock valued at $7,906,000 after purchasing an additional 147,628 shares during the period. BlackRock Inc. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $4,468,000. Finally, Bainco International Investors lifted its stake in shares of Urogen Pharma by 67.2% in the 2nd quarter. Bainco International Investors now owns 175,461 shares of the company’s stock valued at $8,731,000 after purchasing an additional 70,500 shares during the period. 71.11% of the stock is currently owned by institutional investors.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.